Frontiers in Endocrinology · 2020 · 23 citations · 47 references
MedicineEndocrinologyPharmacologyDrug RepurposingImmunotherapyRegenerative MedicineCell-based TherapeuticsCell-based TherapiesDiabetes MellitusGlucagon-like Peptide-1 Receptor AgonistsIncretin-based TherapiesPancreatic EndocrinologyBeta Cell BiologyBeta Cell RegenerationBeta-cell DysfunctionGlucagon-like Peptide 1 SignalingGlucagon-like PeptidesPancreatic Beta-cell FunctionPancreatic Islet CellsPancreatic Regeneration
Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells. An ideal immunotherapy should combine the blockade of the autoimmune response with the recovery of functional target cell mass. With the aim to develop new therapies for type 1 diabetes that could contribute to β-cell mass restoration, a drug repositioning analysis based on systems biology was performed to identify the β-cell regenerative potential of commercially-available compounds. Drug Repositioning is a strategy used for identifying new uses for approved drugs that are outside the scope of the medical indication. A list of 28 non-synonymous repurposed drug candidates was obtained, and 16 were selected as diabetes mellitus type 1 treatment candidates regarding pancreatic β-cell regeneration. Drugs with poor safety profile were further filtered out. Lastly, we selected liraglutide for its predictive efficacy values for neogenesis, transdifferentiation of α-cells and/or replication of pre-existing β-cells. Liraglutide is an analogue of glucagon-like peptide-1, a drug used in patients with type 2 diabetes. Liraglutide was tested in immunodeficient NOD-Scid IL2rg-/- (NSG) with type 1 diabetes. Liraglutide significantly improved blood glucose levels in diabetic NSG mice. During the treatment, a significant increase in -cell mass was observed, due to a boost in -cell number. Both parameters were reduced after withdrawal. Interestingly, islet bihormonal glucagon+insulin+ cells and insulin+ ductal cells arose during treatment. In vitro experiments showed an increase of insulin and glucagon gene expression in islets cultured with liraglutide in normoglycaemia conditions. These results point to β-cell replacement, including transdifferentiation and neogenesis as aiding factors, and support the role of liraglutide in β-cell mass restoration in type 1 diabetes. Understanding the mechanism of action of this drug could have potential clinical relevance in this autoimmune disease.
47
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin, Ignacio Arganda‐Carreras, Erwin Frise et al. · Nature Methods · 2012 · 70.9K citations
KEGG: Kyoto Encyclopedia of Genes and Genomes
Minoru Kanehisa · Nucleic Acids Research · 2000 · 39.2K citations · Full text
KEGG: Kyoto Encyclopedia of Genes and Genomes
Hiroyuki Ogata, Susumu Goto, Kazushige Sato et al. · Nucleic Acids Research · 1999 · 32.4K citations · Full text
KEGG: new perspectives on genomes, pathways, diseases and drugs
Minoru Kanehisa, Miho Furumichi, Mao Tanabe et al. · Nucleic Acids Research · 2016 · 9.4K citations · Full text